Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Hindu
The Hindu
Technology
AFP

Pfizer starts Omicron-specific COVID-19 vaccine trial

Combo photo shows logos Pfizer and BioNTech. (Source: AFP)

Pfizer and its partner BioNTech have begun enrolment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement on January 25.

Pfizer’s CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.